LumaCare

Press Release

September 6, 2005 For Immediate Release

The LumaCare® LC-122M receives the coveted European CE Medical Device approval.

NEWPORT BEACH, CALIFORNIA – Ci-Tec, Ltd., a subsidiary of MBG Technologies, Inc., today announces the LC-122M non-coherent PDT activation device has received CE Medical approval. The approvals include Protocol usage of the LC-122M to activate Photodynamic Drugs such as: ALA, 5-ALA, Foscan®, Levulan®, Metex®, Photofrin®, and others.

"We have finally proven LumaCare's non-coherent light source can activate PDT protocols without the expensive, potentially dangerous laser", said Mark Gart, President of LumaCare®. "Photodynamic Therapy is one of the most exciting new fields in medicine. The costs and dangers of using different lasers for each protocol have made this field prohibitively expensive. The LC-122M is safe, affordable, flexible, and is now approved as an effective non-coherent light source."

The main unit of the LC-122M provides the full spectrum of visible light in a single non-coherent light source, can generate any visible light frequency (400mm-800mm), and activates all currently approved PDT pharmaceuticals and multiple protocols, for total treatment flexibility. The system's interchangeable probes filter and focus the light to a specific frequency and beam pattern. Each probe is protocol-specific and easily connected with a single interlocking connection. Unlike laser-based systems, the LC-122M permits PDT drugs and protocols to be changed in a matter of seconds, along with frequency and power requirements, and do so very cost-effectively.

- - more - -

The LumaCare LC-122M is suitable for all medical disciplines including Veterinary, Dermatology, Oncology, Ophthalmology, and Dental. Because it is a complete solution, it is affordable for our pharmaceutical partners to bundle the LC-122M with new PDT protocol introductions. For physicians and patients, it is a safe and effective PDT drug activation system. This simple and cost-effective approach will appeal to medical insurers and facilitate medical reimbursement.

MBG Technologies recently received a U.S. Patent for LumaCare® Lamp technology. PDT is one of the most promising new fields of medicine to emerge for the non-invasive treatment of tissue diseases and disorders. Photosensitive drugs are applied on the skin and penetrate to the diseased tissue, or are injected into the blood stream from which the affected area absorbs the drug. Once the drugs are in place, they may be selectively activated via specific light frequencies. The LumaCare lamp activates the drugs by irradiating the tissues with a fixed frequency light source unique to each drug and disease. The diseased tissues absorb the drugs, the drugs are activated by the targeted light and destroys the diseased tissues.

For additional information or to place an order, please visit our web site at www.LumaCare.com, or e-mail: info@LumaCare.com.

In Europe, please contact our UK Distributor Lynton Lasers, at Phone: +44 (1477) 5369777.

In the USA, please call the Newport Beach, CA office at 1-949-422-1963.

The LumaCare LC-122M is CE MDD Approved. The LC122M is currently NOT FDA approved. In the USA the LC-122M may be used in research, Veterinary, and commercial applications.